Reuters logo
GSK's Crohn's disease treatment fails in Phase III trial
2013年8月23日 / 下午2点49分 / 4 年前

GSK's Crohn's disease treatment fails in Phase III trial

LONDON, Aug 23 (Reuters) - British pharmaceutical group GlaxoSmithKline Plc said vercirnon, a drug it was developing to treat Crohn’s disease and licensed from ChemoCentryx, had failed in a late-stage clinical trial.

The medicine, which GSK licensed from the California-based company in 2010, did not improve the incidence of adverse events in patients when measured against a placebo, GSK said on Friday, and there was a trend for overall adverse events to increase as dosage levels increased.

The trial failure wiped as much as $242 million, or nearly half, from ChemoCentryx’s value. Its shares were trading down 36 percent at $7.47 at 1438 GMT. GSK’s shares were up 0.3 percent at 1,672 pence, underperforming a 0.7 percent stronger FTSE 100 index.

“The results from the SHIELD-1 study are clearly disappointing but we are committed to further explore the data to determine the way forward to help patients with this chronic debilitating gastrointestinal disease,” said Paul-Peter Tak, senior vice president of GSK’s immuno-inflammation research and development.

The company said new recruitment and dosing in the ongoing clinical trial had been suspended pending further review of the results.

Vercirnon, a type of drug called an antagonist, was being developed by GSK for the potential treatment of inflammatory bowel diseases, such Crohn’s disease, a condition with symptoms such as persistent diarrhoea and abdominal pain.

我们的标准汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below